Burkitt Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin B-cell lymphoma, often associated with Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and chromosomal translocations leading to the overexpression of the oncogene C-MYC. In most cases, Burkitt lymphoma exhibits a specific translocation, t(8;14)(q24;q32), which brings the MYC/c-Myc gene (8q24) in close proximity to the heavy chain immunoglobulin gene (14q32). In rarer instances, this translocation affects chromosome 2 (kappa chain in immunoglobulins) or 22 (lambda chain in immunoglobulins). Burkitt lymphoma can be categorized into three clinical groups: endemic, sporadic, and immunodeficiency-related. The endemic form is associated with malaria and EBV, while the immunodeficiency-related variant is linked to HIV and organ transplantation to a lesser extent. Children generally have a favorable prognosis with intensive chemotherapy treatment, but the outlook for adults is less promising. Pediatric patients are typically staged using the St. Jude staging system, while the Ann Arbor and Murphy staging systems are more commonly employed for adults. The Ann Arbor system considers a patient's symptoms. In contrast, the Murphy staging system is preferred for its ability to highlight extranodal disease and distinguish bone marrow involvement from central nervous system disease. The prognosis depends mainly on clinical and histopathologic staging, particularly the extent of the disease. In general, younger patients tend to have a better prognosis, possibly due to their enhanced ability to tolerate intensive chemotherapy.

·       In the United States, Burkitt lymphoma (BL) incidence was 3.96 per million person-years.

 

Thelansis’s “Burkitt Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Burkitt Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Burkitt Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Burkitt Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Burkitt Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Burkitt Lymphoma, Burkitt Lymphoma market outlook, Burkitt Lymphoma competitive landscape, Burkitt Lymphoma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)